Astria Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2013
Net Income	-81.63	-72.89	-51.83	-219.35	-37.3	-26.29	Upgrade
Share-Based Compensation	7.85	6.31	4.55	3.36	1.39	0	Upgrade
Other Operating Activities	-0.5	-1.87	3.75	161.4	3.43	-0.28	Upgrade
Operating Cash Flow	-74.29	-68.45	-43.53	-30.15	-32.49	-26.57	Upgrade
Capital Expenditures	-0.02	-0.03	-0.09	-0.02	-0.03	-0.01	Upgrade
Acquisitions	0	0	0	6.47	0	0	Upgrade
Change in Investments	-186.15	135.08	-167.04	-19	6.33	-4.07	Upgrade
Investing Cash Flow	-186.17	135.05	-167.13	-12.56	6.3	-4.08	Upgrade
Share Issuance / Repurchase	230.17	88.4	144.72	104.28	40.86	25.62	Upgrade
Financing Cash Flow	230.17	88.4	144.72	104.28	40.86	25.62	Upgrade
Net Cash Flow	-30.29	155.01	-65.94	61.58	14.68	-5.03	Upgrade
Free Cash Flow	-74.31	-68.47	-43.62	-30.17	-32.52	-26.58	Upgrade
Free Cash Flow Per Share	-1.42	-2.27	-2.98	-3.38	-10.63	-14.24	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).